Tags

Type your tag names separated by a space and hit enter

Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia.
Niger J Clin Pract. 2017 04; 20(4):454-458.NJ

Abstract

OBJECTIVE

To determine the correlation between severity of symptoms using the International Prostate Symptom Score (IPSS) and uroflowmetry in patients with lower urinary tract symptoms-benign prostatic hyperplasia (LUTS-BPH).

PATIENTS AND METHODS

We prospectively collected data from 51 consecutive men, who presented with LUTS-BPH at the Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, from January 2012 through December, 2014. Symptom severity was assessed using the self-administered IPSS questionnaire. We also performed uroflowmetry using the Urodyn 1000 (Dantec, serial no. 5534).

RESULTS

The mean age of the patients was 67.2 ± 9.7 years (range 40-89 years). The most common presenting IPSS-LUTS was nocturia (100%) followed by urinary frequency (98%), straining (92.0%), weak stream (84.3%), urgency (41.2%), incomplete voiding (39.2%), and intermittency (35.3%) Most of the patients had moderate symptoms (58.8%) on IPSS with a mean value of 13.5 ± 3.0. The mean Qmax was 15.6 ± 18.7 mL/s and the mean voided volume was 193.0 ± 79.2 mL. About one-third of the patients (39.2%) had an unobstructed flow pattern based on Qmax. Correlation analysis showed a weak correlation between IPSS and voiding time (r = 0.220, P > 0.05), flow time (r = 0.128, P > 0.05), and time to maximum flow (r = 0.246, P > 0.05). These correlations were not significant (P > 0.05). IPSS showed a negative correlation with maximum flow rate (r = 0.368; P < 0.0075), average flow rate (-0.203, P > 0.05), and voided volume (r = -0.164, P > 0.05). This negative correlation was significant for maximum flow rate.

CONCLUSION

Correlation between IPSS and Qmax was negative but statistically significant. This implies that an inverse relationship exists between IPSS and Qmax, and remains the only important parameter in uroflowmetry. There was no statistically significant correlation between IPSS and the other variables of uroflowmetry.

Authors+Show Affiliations

Department of Surgery, Nnamdi Azikiwe University/Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.Department of Surgery, Nnamdi Azikiwe University/Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.Department of Surgery, Nnamdi Azikiwe University/Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28406126

Citation

Oranusi, C K., et al. "Correlation Between International Prostate Symptom Score and Uroflowmetry in Patients With Benign Prostatic Hyperplasia." Nigerian Journal of Clinical Practice, vol. 20, no. 4, 2017, pp. 454-458.
Oranusi CK, Nwofor AE, Mbonu O. Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia. Niger J Clin Pract. 2017;20(4):454-458.
Oranusi, C. K., Nwofor, A. E., & Mbonu, O. (2017). Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia. Nigerian Journal of Clinical Practice, 20(4), 454-458. https://doi.org/10.4103/1119-3077.196120
Oranusi CK, Nwofor AE, Mbonu O. Correlation Between International Prostate Symptom Score and Uroflowmetry in Patients With Benign Prostatic Hyperplasia. Niger J Clin Pract. 2017;20(4):454-458. PubMed PMID: 28406126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia. AU - Oranusi,C K, AU - Nwofor,A E, AU - Mbonu,O, PY - 2017/4/14/entrez PY - 2017/4/14/pubmed PY - 2019/7/2/medline SP - 454 EP - 458 JF - Nigerian journal of clinical practice JO - Niger J Clin Pract VL - 20 IS - 4 N2 - OBJECTIVE: To determine the correlation between severity of symptoms using the International Prostate Symptom Score (IPSS) and uroflowmetry in patients with lower urinary tract symptoms-benign prostatic hyperplasia (LUTS-BPH). PATIENTS AND METHODS: We prospectively collected data from 51 consecutive men, who presented with LUTS-BPH at the Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, from January 2012 through December, 2014. Symptom severity was assessed using the self-administered IPSS questionnaire. We also performed uroflowmetry using the Urodyn 1000 (Dantec, serial no. 5534). RESULTS: The mean age of the patients was 67.2 ± 9.7 years (range 40-89 years). The most common presenting IPSS-LUTS was nocturia (100%) followed by urinary frequency (98%), straining (92.0%), weak stream (84.3%), urgency (41.2%), incomplete voiding (39.2%), and intermittency (35.3%) Most of the patients had moderate symptoms (58.8%) on IPSS with a mean value of 13.5 ± 3.0. The mean Qmax was 15.6 ± 18.7 mL/s and the mean voided volume was 193.0 ± 79.2 mL. About one-third of the patients (39.2%) had an unobstructed flow pattern based on Qmax. Correlation analysis showed a weak correlation between IPSS and voiding time (r = 0.220, P > 0.05), flow time (r = 0.128, P > 0.05), and time to maximum flow (r = 0.246, P > 0.05). These correlations were not significant (P > 0.05). IPSS showed a negative correlation with maximum flow rate (r = 0.368; P < 0.0075), average flow rate (-0.203, P > 0.05), and voided volume (r = -0.164, P > 0.05). This negative correlation was significant for maximum flow rate. CONCLUSION: Correlation between IPSS and Qmax was negative but statistically significant. This implies that an inverse relationship exists between IPSS and Qmax, and remains the only important parameter in uroflowmetry. There was no statistically significant correlation between IPSS and the other variables of uroflowmetry. SN - 1119-3077 UR - https://www.unboundmedicine.com/medline/citation/28406126/Correlation_between_international_prostate_symptom_score_and_uroflowmetry_in_patients_with_benign_prostatic_hyperplasia_ L2 - http://www.njcponline.com/article.asp?issn=1119-3077;year=2017;volume=20;issue=4;spage=454;epage=458;aulast=Oranusi DB - PRIME DP - Unbound Medicine ER -